公开(公告)号：US20210187071A1

公开(公告)日：2021-06-24

申请号：US16754799

申请日：2018-10-26

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Paul B. FISHER ,  Anjan K. PRADHAN ,  Swadesh K. DAS ,  Luni EMDAD

IPC: A61K38/20 ,  A61K31/122 ,  A61K31/5377 ,  A61P35/04

Abstract: In various aspects, the present disclosure provides methods of preventing metastasis to bone in a subject with cancer, as well as compositions and kits for use in the same. In various aspects, the present disclosure provides methods of treating bone metastasis in a subject with cancer, as well as compositions and kits for use in the same. In embodiments, compositions comprise an MDA-7/IL-24 protein.

公开(公告)号：US20190017054A1

公开(公告)日：2019-01-17

申请号：US16068230

申请日：2017-01-06

Applicant: Paul B. FISHER ,  Sarmishta TALUKDAR ,  Luni EMDAD ,  Swadesh K. DAS ,  VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Paul B. FISHER ,  Sarmistha TALUKDAR ,  Luni EMDAD ,  Swadesh K. DAS

IPC: C12N15/113 ,  G01N33/50 ,  A61P35/00 ,  G01N33/574

Abstract: This invention discloses a method of modulating the survival and stemness of cancer stem cells (CSCs) by modulating the expression of MDA-9/Syntenin (SDCBP), which regulates multiple stemness genes, and controls survival of CSCs by activating the pathways, including without limitation NOTCH1. In one embodiment, the stemness genes that can be regulated by modulating expression or activity of MDA-9/Syntenin (SDCBP) includes, but are not limited to, ALDH1A1, AXL, CD44, DDR1, ID1, ITGB1, c-myc, Nanog, NOTCH, Oct4/POU5F1, Sox2, and STAT3. The invention also discloses a method of decreasing/inhibiting CSCs's tumorigenicity and a method of increasing survival of a subject with cancer by suppression of mda-9. This invention provides a method of inhibiting the growth of a cancer, and a method of determining the metastatic or angiogenic potential of a cancer. This invention further provides a method of screening for a candidate compound that modulate the expression or activities of MDA-9/Syntenin (SDCBP).

公开(公告)号：US20230066830A1

公开(公告)日：2023-03-02

申请号：US17787483

申请日：2020-12-18

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Paul B. FISHER ,  Sarmistha TALUKDAR ,  Swadesh K. DAS ,  Anjan PRADHAN ,  Luni EMDAD

IPC: A61K31/519 ,  C12N15/113 ,  A61K31/337 ,  A61K31/439 ,  A61K31/165 ,  A61K31/18 ,  A61K31/4353 ,  A61K38/15 ,  A61K31/336 ,  A61K31/167 ,  A61K31/4406

Abstract: Provided herein are pharmaceutical compositions and methods useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

公开(公告)号：US20210214365A1

公开(公告)日：2021-07-15

申请号：US17148813

申请日：2021-01-14

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY ,  SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

Inventor： Paul B. FISHER ,  Maurizio PELLECCHIA ,  Swadesh K. DAS ,  Timothy P. KEGELMAN ,  Bainan WU ,  Surya K. DE ,  Jun WEI ,  Mitchell E. MENEZES ,  Luni EMDAD

IPC: C07D487/04 ,  A61P35/04 ,  A61K31/519 ,  A61K45/06 ,  C07D495/14

Abstract: Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

公开(公告)号：US20190263824A1

公开(公告)日：2019-08-29

申请号：US16349467

申请日：2017-11-14

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY ,  SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

Inventor： Paul B. FISHER ,  Maurizio PELLECCHIA ,  Swadesh K. DAS ,  Timothy P. KEGELMAN ,  Bainan WU ,  Surya K. DE ,  Jun WEI ,  Mitchell E. MENEZES ,  Luni EMDAD

IPC: C07D487/04 ,  A61K45/06 ,  A61K31/519 ,  A61P35/04

Abstract: Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.